{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:04:24Z","timestamp":1787976264796,"version":"build-2784847793"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The presence of the translocation t(9;22)(q34;q11), leading to the <jats:italic>BCR::ABL1<\/jats:italic> fusion transcript, is the hallmark of chronic myeloid leukemia (CML). Nevertheless, atypical presentation at diagnosis can be challenging. However, although most patients with CML are diagnosed with the e13a2 or e14a2 <jats:italic>BCR::ABL1<\/jats:italic> fusion transcripts, about 5% of them carry rare <jats:italic>BCR::ABL1<\/jats:italic> fusion transcripts, such as e19a2, e8a2, e13a3, e14a3, e1a3, and e6a2. In particular, the e6a2 fusion transcript has been associated with clinically aggressive disease frequently presenting in accelerated or blast crisis phases. To date, there is limited evidence on the efficacy of front-line second-generation tyrosine kinase inhibitors for this genotype. Here, we report two patients, in whom the diagnosis of CML was  challenging. The  use of primers recognizing more distant exons from the common <jats:italic>BCR::ABL1<\/jats:italic> breakpoint region correctly identified the atypical <jats:italic>BCR::ABL1<\/jats:italic> e6a2 fusion transcript. Treatment with the second-generation tyrosine kinase inhibitor nilotinib was effective in our patient expressing the atypical e6a2 <jats:italic>BCR::ABL1<\/jats:italic> fusion transcript.<\/jats:p>","DOI":"10.3389\/fonc.2022.960914","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T05:13:15Z","timestamp":1661749995000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Atypical presentation of patients with chronic myeloid leukemia in chronic phase\u2014Case report"],"prefix":"10.3389","volume":"12","author":[{"given":"Florian","family":"Ramdohr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Fabarius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Bretschneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Monecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus H.","family":"Metzeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes W. G.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Schlenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Kayser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/jnci\/25.1.85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J Natl Cancer Inst"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280175","article-title":"Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study","author":"Gugliotta","year":"2022","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13548","article-title":"Efficacy of dasatinib in a very elderly CML patient expressing a rare E13a3 BCR-ABL1 fusion transcript: A case report","volume":"39","author":"Massimino","year":"2019","journal-title":"Anticancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403079","article-title":"BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis","volume":"17","author":"Schultheis","year":"2003","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02042.x","article-title":"A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia","volume":"109","author":"Branford","year":"2000","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.6.2236.bloodjournal8862236","article-title":"A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia","volume":"88","author":"Hochhaus","year":"1996","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0508-9","article-title":"Is the BCR-ABL1 transcript type in chronic myeloid leukaemia relevant","volume":"30","author":"Langabeer","year":"2013","journal-title":"Med Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.cancergen.2019.06.008","article-title":"A unique case of complex variant translocation of t(6;9;22)(p22;q34;q11.2), der(19) in a newly diagnosed patient with chronic myeloid leukemia","volume":"237","author":"Ciftciler","year":"2019","journal-title":"Cancer Genet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2016.4826","article-title":"Complete cytogenetic response to nilotinib in a chronic myeloid leukemia case with a rare e13a3(b2a3) BCR-ABL fusion transcript: A case report","volume":"13","author":"Liu","year":"2016","journal-title":"Mol Med Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-009-0368-4","article-title":"A chronic myeloid leukemia patient with atypical karyotype and BCR-ABL e13a3 transcript caused by complex chromosome rearrangement","volume":"90","author":"Masuko","year":"2009","journal-title":"Int J Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12616","article-title":"Frequency of rare BCR-ABL1 fusion transcripts in chronicmyeloid leukemia patients","volume":"39","author":"Arun","year":"2017","journal-title":"Int J Lab Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1607329","article-title":"Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts","volume":"60","author":"Xue","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.62","article-title":"Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia","volume":"7","author":"Gong","year":"2017","journal-title":"Blood Cancer J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000230037","article-title":"Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases","volume":"122","author":"Vefring","year":"2009","journal-title":"Acta Haematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1169-4","article-title":"CML with e6a2 BCR-ABL1 transcript: an aggressive entity","volume":"90","author":"Beel","year":"2011","journal-title":"Ann Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404949","article-title":"A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment","volume":"22","author":"Schnittger","year":"2008","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701216402","article-title":"An e6a2 BCR-ABL fusion transcript in a CML patient having an iliac chloroma at initial presentation","volume":"48","author":"Torres","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11933","article-title":"Optimal response in a patient with CML expressing BCR-ABL1 E6A2 fusion transcript with nilotinib therapy: A case report","volume":"34","author":"Manzella","year":"2020","journal-title":"In Vivo"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2021.1221","article-title":"T Lymphoblastic lymphoma with BCR-ABL negative chronic myeloid leukaemia: a novel association","volume":"15","author":"Faizan","year":"2021","journal-title":"Ecancermedicalscience"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/srep14829","article-title":"Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma - a case report","volume":"5","author":"Gruszka","year":"2015","journal-title":"Sci Rep"},{"key":"B24","article-title":"Case report; meta-synchronous triple malignancy in primary diagnosed CML patient","volume":"10","author":"Jamal","year":"2020","journal-title":"Am J Blood Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S300320","article-title":"Hodgkin Lymphoma as a secondary neoplasm during therapy for chronic myeloid leukaemia: Case report and review of the literature","volume":"14","author":"Paczkowska","year":"2021","journal-title":"Onco Targets Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1182\/blood-2019-12983","article-title":"ASXL1 mutations detectable at diagnosis may predict response to imatinib in patients with chronic myeloid leukemia","volume":"134","author":"Machnicki","year":"2019","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403931","article-title":"Coexistence of AML1\/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML","volume":"19","author":"Corm","year":"2005","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1894652","article-title":"Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia","volume":"62","author":"Adnan-Awad","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3390\/cells9071639","article-title":"EZH2 in myeloid malignancies","volume":"9","author":"Rinke","year":"2020","journal-title":"Cells"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2731","article-title":"Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms","volume":"45","author":"Kon","year":"2013","journal-title":"Nat Genet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.960914\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T05:13:21Z","timestamp":1661750001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.960914\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":30,"alternative-id":["10.3389\/fonc.2022.960914"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.960914","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,29]]},"article-number":"960914"}}